Goserelin (acetate)

Goserelin (acetate)

CAT N°: 24071
Price:

From 48.00 40.80

Goserelin is a synthetic gonadotropin-releasing hormone (GNRH) agonist that binds to the GNRH receptor (GNRHR; Ki = 1.6 nM, in CHO cells expressing the human receptor).{36464} It binds to mouse pituitary ?T3-1 cells and human placenta (Kds = 2 and 580 nM, respectively) and increases intracellular calcium in ?T3-1 cells.{36465} Goserelin induces testosterone production in vitro within 4 h in rat Leydig cells (ED50 = 83 nM) but decreases testosterone plasma level in vivo in rats over a period of 2 to 24 weeks.{36466,36467} It inhibits tumor growth in a DU145 human prostate carcinoma mouse xenograft model when administered at a dose of 100 ?g per day.{36468} Formulations containing goserelin have been used in the treatment of hormone-dependent breast and prostate cancers, as well as endometriosis and uterine fibroids.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-(aminocarbonyl)hydrazide-6-[O-(1,1-dimethylethyl)-D-serine]-1-9-luteinizing hormone-releasing factor (swine), acetate
  • Correlated keywords
    • 65807-02-5 145781-92-6 zoladex Chinese hamster ovary ?T31 DU-145 ICI118630 ICI 118630 2-(aminocarbonyl)hydrazide-6-[O-(1,1-dimethylethyl)-D-serine]-1-9-luteinizing hormone-releasing factor (swine), monoacetate
  • Product Overview:
    Goserelin is a synthetic gonadotropin-releasing hormone (GNRH) agonist that binds to the GNRH receptor (GNRHR; Ki = 1.6 nM, in CHO cells expressing the human receptor).{36464} It binds to mouse pituitary ?T3-1 cells and human placenta (Kds = 2 and 580 nM, respectively) and increases intracellular calcium in ?T3-1 cells.{36465} Goserelin induces testosterone production in vitro within 4 h in rat Leydig cells (ED50 = 83 nM) but decreases testosterone plasma level in vivo in rats over a period of 2 to 24 weeks.{36466,36467} It inhibits tumor growth in a DU145 human prostate carcinoma mouse xenograft model when administered at a dose of 100 ?g per day.{36468} Formulations containing goserelin have been used in the treatment of hormone-dependent breast and prostate cancers, as well as endometriosis and uterine fibroids.

We also advise you